CRISPR Overhauls CAR-T Pipeline With Next-Gen Candidates, Autoimmune Expansion
Experts see allogeneic CAR-Ts as less likely to carry potential risks of T-cell malignancies, and an opportunity for differentiation against the crowded autologous CD19-directed CAR-T space.
You may also be interested in...
Kyverna CEO Peter Maag spoke with Scrip about the company’s five-year overnight success after its well-received IPO. Metagenomi and Telomir also went public in the US in smaller offerings.
Deal Snapshot: The Roche subsidiary will use GenEdit’s hydrophilic nanoparticles to develop genetic medicines for autoimmune diseases meant to overcome the limitations of existing delivery methods.
TG, which has seen growing sales for Briumvi in multiple sclerosis, is expanding into CAR-T for immunology as Precision pivots to in vivo gene therapies.